Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Dentists Identify Breast Cancer from Saliva Proteins

By Labmedica staff writers
Posted on 23 Jan 2008
Protein markers in saliva can distinguish women with breast cancer from those with benign tumors and those with healthy cells. More...
These findings potentially could enable dentists and physicians to detect breast cancer during routine office visits.

A study was performed to determine whether protein byproducts secondary to cancer- related oncogenes appear in the saliva of breast cancer patients. Dr. Charles Streckfus, professor of diagnostic sciences at the University of Texas (UT) Health Science Center (Houston, TX, USA) and colleagues analyzed saliva samples from 30 women--10 with benign tumors, 10 with malignant tumors, and 10 without tumors. They found 49 proteins that differentiated between the women with tumors and those without. In a previous study, Prof. Streckfus identified 85% of malignancies with one differing breast cancer protein; a rate he estimated could approach 95% if additional proteins were analyzed.

In this study, with additional analysis, the scientists were able to distinguish between benign and malignant tumors. According to Prof. Streckfus, the extra analysis could help eliminate false-positive results and allow doctors to determine the next treatment options for women with breast cancer.

A large, multicenter trial is planned in about two years at the UT M.D. Anderson Cancer Center (Houston, Texas, USA) and the UT Dental Branch (Houston, Texas, USA). The proposed test will be conducted on a gold-plated chip or lab dish. A laser will then be used to distinguish protein markers in saliva applied to the chip. Such a test would be used in conjunction with other tools, including mammograms. There are currently no blood tests available for detecting breast cancer.

"This will be a noninvasive, quick means of detection,” Prof. Streckfus said about the new test. "With it, dentists will be able to catch cancers before a woman can feel a lump.”

Prof. Streckfus noted that the test could be useful for breast cancer survivors who need to be monitored regularly and also in developing countries that lack mammography technology.


Related Links:
University of Texas Health Science Center
M.D. Anderson Cancer Center
University of Texas Dental Branch

Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
HPV Molecular Test
BD Onclarity HPV Assay
Steam Sterilizer
Hi Vac II Line
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The study compares rapid molecular CPE diagnostics, which can return results in about one hour, with culture-based screening, which typically takes about 48 hours (Image credit: Adobe Stock)

Rapid Molecular Screening Aims to Accelerate Hospital Infection Control for CPE

Drug-resistant infections remain a critical patient-safety threat in hospitals, with carbapenemase-producing Enterobacterales (CPE) among the most urgent concerns. In England, reports of acquired carbapenemase... Read more

Industry

view channel
Image: The partnership aims to broaden access to ultrasensitive blood-based testing for multiple myeloma and other hematologic malignancies (Image credit: 123RF)

Partnership Expands Ultrasensitive Blood-Based Diagnostics for Hematologic Malignancies

Predicta Biosciences (Cambridge, MA, USA) and CIMA LAB Diagnostics at Clínica Universidad de Navarra (Pamplona, Spain) have entered an agreement to provide a joint service that combines CIMA LAB’s flow... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.